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Spondweni virus (SPOV) is the flavivirus that is most
closely related to Zika virus (ZIKV). Although SPOV
causes sporadic human infections in Africa, recently
it was found in Culex mosquitoes in Haiti. To investi-
gate the pathogenic spectrum of SPOV, we devel-
oped infection models in mice. Although two SPOV
strains failed to cause disease in immunocompetent
mice, each accumulated in the brain, spleen, eye,
testis, and kidney when type I interferon signaling
was blocked and unexpectedly caused infection, im-
mune cell infiltration, and swelling in the ankle. In
pregnant mice, SPOV replicated in the placenta and
fetus but did not cause placental insufficiency or
microcephaly. We identified human antibodies from
ZIKV or DENV immune subjects that neutralized
SPOV infection and protected against lethal chal-
lenge. Our experiments describe similarities and dif-
ferences in clinical syndromes between SPOV and
ZIKV and suggest that their serological relatedness
has implications for antibody therapeutics and flavi-
virus vaccine development.
INTRODUCTION
Spondweni virus (SPOV), a member of the same serogroup as
Zika virus (ZIKV), is a mosquito-transmitted flavivirus that histor-
ically has circulated in sub-Saharan Africa. In 1952, the Chuku
strain of SPOV was isolated from a patient in Nigeria, but
cross-reactivity in neutralization tests led to its initial misclassifi-
cation as a ZIKV strain. Until subsequent analysis clarified the
identity of SPOV-Chuku (Draper, 1965), the 1955 South African
SPOV-SA Ar94 mosquito isolate was considered the prototype
SPOV strain (Kokernot et al., 1957; MacNamara, 1954). Although
most symptomatic SPOV infections result in mild illness, a
subset of cases are believed to progress to more serious dis-
ease, including vascular leakage and neurological involvement
(Haddow and Woodall, 2016).
The enzootic cycle of SPOV is not entirely defined, but it is
likely propagated between mosquitoes and non-human pri-
mates (Haddow et al., 2016). In contrast to other flaviviruses
(e.g., Dengue, Zika, and West Nile viruses), SPOV infection and
dissemination historically was low or non-existent in Aedes ae-
gypti,Aedes albopictus, andCulex quinquefasciatusmosquitoes
following infectious blood feeding of SPOV strains (Haddow
et al., 2016). However, isolations of SPOV from eight other
species of mosquitoes in the genera Aedes, Culex, Eretmapo-
dites, and Mansonia have been reported. Based on its vector
biology, it has been speculated that SPOV has limited potential
for urban epidemic cycles (Haddow et al., 2016). However, the
epidemiologymay be changing, as recently, SPOVwas detected
in field-caught Culex quinquefasciatus mosquitoes in Haiti in
2016 (White et al., 2018).
SPOV has a positive-sense, single-stranded RNA genome of
approximately 11 kb in length (Pierson and Diamond, 2013).
SPOV-Chuku and SPOV-SA Ar94 share 98% nucleotide and
99% amino acid identity to each other and 68% nucleotide
and 75% amino acid identity to ZIKV, the closest flavivirus rela-
tive (Haddow et al., 2016). Sequencing of RNA from SPOV-
infected mosquitoes from Haiti revealed 96.8% and 98.8%
nucleotide and 98.3% and 98.8% amino acid identity with
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SPOV-Chuku and SPOV-SA Ar94 strains, respectively (White
et al., 2018). Despite the close genetic relationship to ZIKV, little
is known regarding the pathogenesis of SPOV infections and its
clinical syndromes.
Here, we investigated the tropism and disease potential of
SPOV in mice. SPOV, like ZIKV (Lazear et al., 2016; Rossi
et al., 2016), did not replicate efficiently in wild-type (WT)
C57BL/6 immunocompetent mice after subcutaneous inocula-
tion. However, administration of an anti-Ifnar1 blocking mono-
clonal antibody (mAb) rendered animals susceptible to infection
and disease by the two prototype strains, SPOV-Chuku and
SPOV-SA Ar94. Mice treated with anti-Ifnar1 mAb sustained
high levels of SPOV infection inmultiple tissues, including serum,
spleen, kidney, and brain at 7, 14, and 21 days post-infection
(dpi). Unexpectedly, persistent viral RNA was measured in the
serum up to 56 dpi, and this finding occurred despite the induc-
tion of adaptive B and T cell responses. Moreover, both SPOV
strains had the capacity to induce foot swelling, which is not
typical of flaviviruses and is instead reminiscent of the musculo-
skeletal disease observed following alphavirus infection (Morri-
son et al., 2011). We also assessed the ability of SPOV to infect
the placenta and developing fetus in the context of pregnancy.
Although SPOV was detected in the placenta and fetal head at
embryonic day (E)13.5, overt fetal pathology was not observed.
Finally, our studies discerned the serological relatedness of
SPOV, ZIKV, and DENV and established that cross-reactive
anti-ZIKV and anti-DENV human mAbs can neutralize SPOV
infection in cell culture and protect against disease in vivo.
Collectively, our studies establish diseasemodels of SPOV path-
ogenesis in mice and define potential protective countermea-
sures with therapeutic antibodies.
RESULTS
SPOV Pathogenesis in Mice
To begin to understand whether SPOV causes a similar disease
pathogenesis to the closely related ZIKV, we developed amouse
model of infection. Although a recent study used AG129
mice lacking both type I interferon (IFN) (a/b) and II IFN (g) recep-
tors to assess SPOV tropism in the male reproductive tract
(McDonald et al., 2017), we sought to establish a less immuno-
compromised model, which might have greater utility in evalu-
ating viral pathogenesis and host immune responses. Groups
of 8-week-old male C57BL/6 mice were treated with an anti-
Ifnar1-blocking mAb (MAR1-5A3) 1 day prior to subcutaneous
inoculation in the foot with prototype SPOV strains SA Ar94
(South Africa, 1955) or Chuku (Nigeria, 1952; Figure 1). Of note,
contemporary infectious isolates from Haiti are not yet available.
We confirmed the identity of SPOV SA Ar94 and SPOV-Chuku
strains by next-generation sequencing and also established
that no other adventitious pathogens were present in our viral
stocks. Mice that did not receive anti-Ifnar1 mAb exhibited no
weight loss, morbidity, or mortality after inoculation with either
SPOV strain (Figures 1A–1D). In comparison, mice inoculated
with SPOV-SA Ar94 and pretreated with 0.5, 1, or 2 mg of anti-
Ifnar1 mAb had 33%, 66%, and 100% mortality rates, respec-
tively (Figure 1A). Mice inoculated with SPOV-Chuku had
lethality rates of 66%–90% when pretreated with 0.5 or 1 mg
of anti-Ifnar1 mAb (Figure 1C). Consistent with these results,
mice that ultimately succumbed to infection began to loseweight
by 5 dpi with either SPOV-SA Ar94 or SPOV-Chuku. By 9 (SPOV-
SA Ar94) or 12 (SPOV-Chuku) dpi, animals had lost between
15% and 30% of their starting body weight (Figures 1B and
1D). We also investigated the pathogenic potential of SPOV in
3-week-old male mice in which the human STAT2 gene was
introduced into the mouse STAT2 locus (hSTAT2 KI) in the
absence of anti-Ifnar1 mAb treatment; these mice were tested
because they enabled ZIKV to overcome murine innate immune
restriction and cause pathogenesis (Gorman et al., 2018). How-
ever, unlike ZIKV, SPOV NS5 protein did not promote degrada-
tion of human STAT2; nonetheless, SPOV NS5 did bind human
STAT2, which could antagonize its innate immune functions
through other mechanisms (Grant et al., 2016). In contrast to re-
sults with ZIKV, hSTAT2 KI mice did not exhibit weight loss,
morbidity, or mortality and sustained little viral infection at
7 dpi with SPOV-SA Ar94 (Figure S1).
In the course of the infection studies of WT C57BL/6 mice, we
noticed swelling in the feet of mice inoculated with SPOV-SA
Ar94 (Figures 1E and 1F) or SPOV-Chuku (Figures 1G and 1H).
SPOV-SA Ar94 caused modest swelling (10%–20% increase in
size) in the ipsilateral foot at 5 dpi and only when anti-Ifnar1
mAb was administered. In comparison, mice infected with
SPOV-Chuku and pretreated with 0.5 or 1 mg of anti-Ifnar1
mAb had approximately 50% or 80% increases in ipsilateral
foot size at 5 dpi, respectively (Figure 1I). Remarkably, the
contralateral foot also developed swelling after SPOV-Chuku
infection, with an approximately 10%–20% increase in size at
5 dpi when the mice were pretreated with 0.5 or 1 mg of anti-
Ifnar1, respectively. Flow cytometric analysis of the ipsilateral
foot at 5 dpi revealed a substantial increase in immune cell infil-
tration in mice pretreated with 1 mg of anti-Ifnar1 and inoculated
with SPOV-Chuku in comparison to mock-infected, anti-Ifnar1-
treated control animals (Figure 1J). We observed a greater than
300-fold increase in CD45+ leukocytes in the feet of SPOV-
Chuku-infected animals, with markedly higher numbers of
monocytes, neutrophils, NK cells, CD8+ T cells, CD4+ T cells,
and B cells in the joint-associated tissues.
SPOV Tissue Tropism in Mice
We assessed the tissue tropism of SPOV by measuring the viral
burden at 7, 14, and 21 dpi. SPOV strains replicated inefficiently
in WT mice without anti-Ifnar1 mAb pretreatment, with levels of
viral RNA (Table S1) above background observed consistently
only in the ipsilateral foot at 7 dpi. In comparison, mice pre-
treated with 0.5 or 1 mg of anti-Ifnar1 mAb had approximately
103 to 105 FFU equivalents/g of SPOV-SA Ar94 or SPOV-Chuku
in the serum, brain, spleen, testes, kidney, ileum, and eye at 7 dpi
(Figures 2A and 2B). Mice inoculated with SPOV-SA Ar94 or
SPOV-Chuku both sustained high levels of SPOV RNA (105–
106 FFU equivalents/g) in the ipsilateral and contralateral feet
at 7 dpi. At 14 dpi, mice infected with SPOV-SA Ar94 or SPOV-
Chuku and treatedwith 0.5mg anti-Ifnar1mAb generally showed
waning titers with a 10-fold reduction in viral RNA in most tis-
sues compared to 7 dpi (Figures 2C and 2D). By 21 dpi, most
mice inoculated with SPOV-SA Ar94 had cleared infection in
the ileum and eye yet still showed residual viral RNA in the serum,
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spleen, and brain (Figure 2E). Mice infected with SPOV-Chuku
sustained greater viral persistence at 21 dpi in several sites,
including the serum, brain, spleen, and feet (Figure 2F). Because
of the persistent viremia at 21 dpi, we performed a longitudinal
study in mice treated with 0.5 mg of anti-Ifnar1 mAb and inocu-
lated with SPOV-SA Ar94. Remarkably, viremia was detected in
serum until approximately 56 dpi (Figure 2G).
T and B Cell Responses to SPOV Infection
Given the unexpected persistence of SPOV in some tissues, we
evaluated B and T cell responses and compared them to those
observed after ZIKV infection. WT mice were pretreated with
0.5 mg of anti-Ifnar1-blocking mAb, inoculated with SPOV-SA
Ar94 or ZIKV (Dakar 41525), and ex vivo responses of splenic
T cells were assessed 8 days later, utilizing aDb-restricted immu-
nodominant ZIKV-derived 9-mer peptide (E294–302; Elong Ngono
et al., 2017) that cross-reacts with SPOV (Figure 3A). The corre-
sponding SPOV E protein peptide has three differences at amino
acids 296 (p3 of the peptide: valine to isoleucine), 297 (p4: serine
to glycine), and 302 (p9: valine to isoleucine); these changes
do not alter or are compatible with anchor residues at p2 and
p9 (Falk et al., 1991). Relative to uninfected mice, the numbers
of CD8+ T cells expressing the cytotoxicity marker granzyme B
were increased and similar between SPOV- and ZIKV-infected
mice. The numbers of CD8+ T cells expressing IFNg after peptide
restimulation were increased in ZIKV-infected mice relative
to SPOV-infected mice, which could reflect the sequence
mismatch of the peptide used for restimulation. Notwithstanding
this difference, SPOV-infected mice clearly had a higher number
of IFNg+ CD8+ T cells than naive mice. Together, with the gran-
zyme B responses, this finding confirmed induction of antigen-
specific CD8+ T cell responses in SPOV-infected mice. Differ-
ences in the frequency or total number of CD4+ T cells were
not observed among the three groups (Figure 3A).
Because of the persistent viremia, we evaluated the humoral
immune responses. Initially, we assessed the antiviral antibody
response at days 7, 14, and 21 after SPOV-SA Ar94 inoculation
of mice that were not treated or treated with anti-Infar1 mAb.
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Figure 1. Clinical Consequences of SPOV Infection in Mice
(A–D) Survival and weight loss analysis. 8-week-old C57BL/6 male mice were pretreated at day1 with no antibody or a single dose of anti-Ifnar1 mAb (0.5, 1, or
2 mg) and then mock-infected or inoculated with 106 FFU of SPOV-SA Ar94 (A and B) or 105 FFU of SPOV-Chuku (C and D) and followed for survival (A and C) or
weight change (B and D). Survival analysis was compared to the uninfected mice (log rank test with Bonferroni post-test: n.s., not significant; **p < 0.01; ****p <
0.0001). Weight change was compared to the uninfectedmice (Kruskal-Wallis ANOVAwith Dunnett’s post-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Data are from two experiments with n = 9 to 10 animals per group. See also Figure S1.
(E–H) C57BL/6 male mice were inoculated with SPOV-SA Ar94 (E and F) or SPOV-Chuku (G and H) as described above. On days 1–7 post-infection, ipsilateral
(E and G) and contralateral (F and H) foot swelling was measured using digital calipers and compared to the day 0 time point (Kruskal-Wallis ANOVA with
Dunnett’s post-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are from two experiments with n = 9 to 10 animals per group.
(I) C57BL/6malemicewere inoculated with SPOV-Chuku, and peak swelling was observed in the ipsilateral foot on day 5. Representative images from uninfected
(left) and SPOV-Chuku infected mice (right) are shown.
(J) Flow cytometric analysis of uninfected and SPOV-Chuku-inoculated ipsilateral feet at 5 dpi. Both cohorts of mice received 1 mg of anti-Ifnar1 at day 1. Cell
numbers of each immune cell subset were compared (Mann-Whitney test: ****p < 0.0001). Data are from two experiments with n = 9 to 10 animals per group.
For (B), (D), and (E)–(H), error bars indicate SEM. For (J), bars denote median values.
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Figure 2. Viral Burden in SPOV-Infected Mice
(A–F) 8-week-old C57BL/6 male mice were pretreated at day 1 with no antibody or a single dose of anti-Ifnar1 mAb (0.5 or 1 mg) and then inoculated with 106
FFU of SPOV-SA Ar94 (A, C, and E) or 105 FFU of SPOV-Chuku (B, D, and F). Serum and tissues (brain, spleen, testis, kidney, ileum, and eye) were harvested at
days 7 (A and B), 14 (C and D), or 21 (E and F) after infection, and SPOV RNA levels were measured by qRT-PCR. Viral RNA levels were compared to tissues from
the no anti-Ifnar1mAb-treatedmice (one-way ANOVAwith Dunnett’s post-test: ***p < 0.001; ****p < 0.0001). Data are from two experiments: day 7, n = 10; day 14,
n = 7 to 10; and day 21, n = 8–10. Bars denote median values.
(G)Micewere pre-treated at day1with a single dose of anti-Ifnar1mAb (0.5mg) and then inoculatedwith 106 FFU of SPOV-SAAr94. Serumwas collected on the
indicated days, and SPOV RNA was measured by qRT-PCR. Data are from two experiments with n = 5–20 animals per time point. Data points on the dotted lines
were not measurable and given the arbitrary value of the limit of detection (LOD).
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Serum frommice that did not receive anti-Ifnar1 mAb had higher
neutralizing antibody titers at 14 and 21 dpi compared to 0 and 7
dpi (Figure 3B). Serum from mice treated with 0.5 mg of anti-
Ifnar1 mAb prior to SPOV-SA Ar94 infection showed neutralizing
activity at 7 dpi, which plateaued thereafter (Figure 3C). To
extend these findings, in animals infected with SPOV and treated
with anti-Ifnar1 mAb, we measured the antiviral immunoglobulin
M (IgM) and IgG responses in serum by ELISA using purified, re-
combinant ectodomain (amino acids 2–412) of SPOV E protein
(Figures 3D and 3E). IgM levels peaked at 7 dpi and then
decreased over time, whereas IgG levels peaked at 14 dpi and
were similar at 21 dpi. As the lack of augmentation of the anti-
SPOV IgG response after day 14 might contribute to the persis-
tent viremia, we compared the antibody response after ZIKV
infection, where viremia in serum is cleared within 21 dpi (Govero
et al., 2016). However, similar to SPOV, serum from ZIKV-in-
fected mice pretreated with anti-Ifnar1-blocking mAb reached
peak neutralizing antibody titer at 7 dpi and did not increase
further at 14 and 21 dpi (Figure 3F). An ELISA with purified
ZIKV E ectodomain protein showed peak IgM levels at 7 dpi (Fig-
ure 3G) and constant levels of ZIKV-specific IgG levels at 7, 14,
and 21 dpi (Figure 3H), results that were analogous to those
seen after SPOV infection. Thus, in mice treated with anti-Ifnar1
mAb, SPOV and ZIKV infection induced similar humoral re-
sponses, yet viremia persisted for a longer duration after SPOV
infection.
SPOV Infection during Pregnancy
To determine whether SPOV has a similar potential for causing
placental damage and fetal demise as ZIKV, we adapted amodel
of ZIKV infection during pregnancy (Miner et al., 2016). WT dams
were treated with either 0, 0.5, or 1 mg of anti-Ifnar1 mAb on
E5.5, inoculated with SPOV-SA Ar94 on E6.5 via footpad injec-
tion, andmaternal and fetal tissues were collected on E13.5 (Fig-
ure 4). The levels of SPOV RNA roughly correlated with the dose
of anti-Ifnar1 mAb administered, with a trend toward higher
levels of SPOV RNA in the serum and brain in dams receiving
the 1 mg dose. However, levels of SPOV RNA in the spleen at
Uninfected SPOV SA Ar94 ZIKV Dakar 2.1.1V
CD19+ CD4+ CD44+ 
CD4+
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Figure 3. Immune Responses after SPOV or ZIKV Infection
8-week-old C57BL/6 male mice were uninfected or pretreated at day 1 with a single 0.5-mg dose of anti-Ifnar1 mAb and then inoculated with 106 FFU of
SPOV-SA Ar94 or ZIKV Dakar 41525.
(A) At 8 dpi, spleens were harvested and processed by flow cytometry. The total number of indicated cell populations (CD19+, CD4+, CD44+ CD4+, CD8+, and
granzyme B+ CD8+) is shown. Cells also were incubated with an immunodominant CD8+ T cell peptide and stained intracellularly for IFN-g. Cell numbers were
compared to those obtained from uninfected mice (one-way ANOVA with Dunnett’s post-test: **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are from three
experiments with n = 8–10 mice per group.
(B–E) Antibody responses after SPOV infection. Mice were pretreated at day 1 with no mAb (B) or a single 0.5-mg dose of anti-Ifnar1 mAb (C–E) and then
inoculated with 106 FFU of SPOV-SA Ar94. Serum was harvested at days 0, 7, 14, and 21 after infection and processed for neutralizing activity (B and C) or anti-
SPOV IgM (D) and anti-SPOV IgG (E) binding to recombinant SPOV E protein. Data are from two experiments with n = 3–9 mice per group.
(F–H) Antibody responses after ZIKV infection. Mice were pretreated at day1 with a single 0.5-mg dose of anti-Ifnar1 mAb and then inoculated with 106 FFU of
ZIKV-Dakar 41525. Serum was harvested at days 0, 7, 14, and 21 after infection and processed for neutralizing activity (F) or anti-ZIKV IgM (G) and anti-ZIKV IgG
(H) binding to recombinant ZIKV E protein. Data are from two experiments with n = 3–11 mice per group.
Neutralization and binding data in (B)–(H) were compared to day 0 samples (one-way ANOVA with Dunnett’s post-test: **p < 0.01; ***p < 0.001; ****p < 0.0001).
Data points on the dotted lines were not measurable and given the arbitrary value of the LOD. In this figure, bars denote median values.











































































































































































Figure 4. SPOV Infection at the Maternal-Fetal Interface
(A–C) 8- to 10-week-old pregnant C57BL/6 dams were treated on E5.5 with no mAb or anti-Ifnar1 mAb (0.5 or 1 mg) and then inoculated via subcutaneous route
with 106 FFU of SPOV-SA Ar94 on E6.5. At E13.5, maternal (A) and fetal (B and C) tissues were processed for SPOV RNA (A and B) or infectious virus (C) by qRT-
PCR and plaque assays, respectively. Levels of viral RNA or infectious virus were compared to those obtained from mice treated with no mAb (one-way ANOVA
with Dunnett’s post-test: **p < 0.01; ***p < 0.001; ****p < 0.0001). Data are from two experiments: n = 4, 4, and 2 dams for the 0-, 0.5-, and 1-mg anti-Ifnar1 groups;
n = 14, 15, and 8 fetuses for the 0-, 0.5-, and 1-mg anti-Ifnar1 mAb groups.
(D) RNA ISH staining of placentas at E13.5 from SPOV-infected dams. Low-power (403: scale bars represent 200 mm) and high-power (2003: scale bars
represent 50 mm) images are presented in sequence (top and bottom panels). The images are representative of placentas from 2 to 3 dams.
(legend continued on next page)
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7 dpi were similar in dams receiving 0.5 or 1 mg of anti-Ifnar1
mAb (Figure 4A). Dams that did not receive anti-Ifnar1 mAb sus-
tained minimal or no SPOV infection in maternal or fetal tissues.
Dams treated with anti-Ifnar1 mAb and inoculated with SPOV
showed placental infection and vertical transmission to the
developing fetus. Generally, higher amounts of SPOV RNA
were detected in the placentas compared to the fetal heads (Fig-
ure 4B), and infectious virus (105–106 plaque-forming units
[PFU]/g) was recovered only from the placentas and not the fetal
heads (Figure 4C).
Given the high levels of SPOVRNA in the placenta yet relatively
low levels in fetal heads, we performed RNA in situ hybridization
(ISH) to better define the tropism of infection. We detected iso-
lated SPOV RNA-positive cells that localized predominantly to
the junctional zone of the placenta in dams treated with anti-
Ifnar1mAb (Figure 4D). This pattern of viral RNA staining is similar
to ZIKV infection at a similar gestational time point (Jagger et al.,
2017). However, we did not observe significant differences in the
fraction of resorbed fetuses in the SPOV-infected dams at E13.5
or E18 relative to the uninfected dams (Figures 4E and 4F). There
also were no differences in occipital-frontal fetal head diameter
or fetus length at E13.5 when comparing SPOV-infected and un-
infected groups (Figures 4G and 4H). Thus, although SPOV is
capable of propagating at the maternal-fetal interface, unlike
ZIKV (Miner et al., 2016), it does not appear to cause extensive
placental damage or fetal demise in mice.
Serological Relatedness of SPOV, ZIKV, and DENV
To confirm the functional relationship of antibody responses to
SPOV and explore the potential for cross-neutralization or
enhancement of related flaviviruses (e.g., ZIKV and DENV), we
tested sera from convalescent mice after ZIKV or SPOV infection
for their ability to inhibit SPOV, ZIKV, or DENV2 infection (Figures
5A–5C and S2). Neutralization was evaluated using reporter virus
particles (RVPs) produced with the structural proteins of each
flavivirus. As expected, naive sera failed to neutralize or enhance
SPOV, ZIKV, or DENV2 RVPs (Figures 5A and S2). ZIKV-immune
mouse sera strongly neutralized ZIKV (serum dilution EC50 of
1/14,049) and moderately neutralized SPOV (EC50 of 1/499) but
showed little inhibition against DENV2 (EC50 < 1/100; Figures
5B and S2). In contrast, SPOV-immune murine sera strongly
neutralized SPOV (EC50 of 1/5,009) and moderately neutralized
ZIKV (EC50 of 1/327) but showed little inhibitory activity against
DENV2 (EC50 < 1/100; Figures 5C and S2). Sub-neutralizing
levels of ZIKV- or SPOV-immune sera enhanced infection of all
three flaviviruses in cells expressing Fcg receptors (Figure S2).
Because ADE and neutralization of flaviviruses are a function
of multiple-hit model of antibody occupancy of the virion, within
a given FcgR-expressing cell population near the threshold of
neutralization, ADE is observed in some cells whereas neutrali-
zation occurs in others (Pierson et al., 2007). These functional
data confirm that ZIKV and SPOV are distinct viruses within the
same serogroup and that cross-reactive polyclonal antibodies
(pAbs) derived from murine infections can enhance ZIKV,
SPOV, and DENV infection in cell culture.
We next tested sera from convalescent humans after ZIKV or
DENV infection for their ability to inhibit or enhance SPOV, ZIKV,
or DENV2 infection (Figures 5D, S3, and S4). Sera from convales-
cent ZIKV-infected individuals most potently inhibited ZIKV
(EC50 of 1/7,822), moderately inhibited SPOV (EC50 of 1/564),
(E and F) Fetal outcome is presented as frequency of intact versus resorbed fetuses at the time of harvest at E13.5 (E) or E18 (F). The number of fetuses analyzed
are as follows: (E) 33, 34, and 20 fetuses for no mAb, 0.5 mg of anti-Ifnar1 mAb, and 1 mg of anti-Ifnar1 mAb, respectively and (F) 37 and 41 fetuses for uninfected
and SPOV-infected (after 0.5 mg anti-Ifnar1 treatment), respectively.
(G and H) Measurements of fetal head diameter (G) and length (H). Bars indicate median values. Significance was analyzed by one-way ANOVA with a Dunnett’s
post-test (all comparisons were not statistically different). Each point represents data from an individual fetus. Data points on the dotted lines were not
measurable and given the arbitrary value of the LOD.
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Figure 5. Serological Relatedness of SPOV, ZIKV, and DENV
Neutralization assayswere performed using ZIKV, SPOV, andDENV2GFP reporter virus particles (RVPs). Serial dilutions of sera from naive (A), immunemice after
ZIKV (B) or SPOV infection (C), or ZIKV convalescent humans (D) were incubated with indicated RVPs and used to infect a DC-SIGNR-expressing Raji cell line.
GFP-expressing cells were measured by flow cytometry at 24–48 h post-infection, depending on the virus. Nonlinear regression analysis was used to determine
the dilution of sera at half-maximal neutralization of infection (EC50). Line graphs represent reciprocal EC50 titers for individual serum samples against indicated
viral strains (mouse serum: naive [n = 4], ZIKV-infected [n = 5], and SPOV-infected [n = 5]; human serum: ZIKV convalescent [n = 5]). Mean EC50 was analyzed by
two-way ANOVA with Tukey’s post-test (****p < 0.0001). Error bars indicate the SEM from two experiments of duplicate technical replicates. Dotted lines
represent the limit of detection (1:100 dilution for mouse sera; 1:60 dilution for human sera). See also Figures S2, S3, and S4.
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and exhibited low neutralizing activity against DENV2 (EC50 <
1/60). One individual may have had previous flavivirus exposure,
as the serum neutralized ZIKV and DENV2 RVPs at similar
titers (EC50 of 1/3,568). Sera from convalescent DENV-infected
individuals moderately neutralized DENV2 (EC50 of 1/337) and
weakly inhibited ZIKV (EC50 of 1/90) but had little blocking activ-
ity against SPOV (EC50 < 1/30). In comparison, convalescent
human sera from ZIKV- or DENV-infected individuals enhanced
infection of all three flaviviruses (Figures S3 and S4).
Anti-DENV and Anti-ZIKV Human mAbs Inhibit SPOV
Infection in Mice
Given the serological data, we predicted that a subset of cross-
reactive mAbsmight neutralize SPOV infection in cell culture and
protect in vivo. E-dimer epitope (EDE)mAbs isolated fromDENV-
infected patients bind to an inter-dimer quaternary epitope and
cross-neutralize ZIKV infection (Barba-Spaeth et al., 2016; Dej-
nirattisai et al., 2015, 2016; Fernandez et al., 2017). Indeed,
EDE1 mAbs (e.g., EDE1-B10, EDE1-A9, and EDE1-C4) strongly
inhibited infection of SPOV in cell culture (EC50 of 7, 131, and
23 ng/mL, respectively; Figure 6A). We separately screened
a panel of human anti-ZIKV-neutralizing mAbs (Sapparapu
et al., 2016) for their ability to inhibit SPOV infection. ZIKV-117
(DII-dimer epitope), ZIKV-A7 (DIII epitope), and ZIKV-C10 (DIII
epitope) neutralized SPOV infection (EC50 of 384, 72, and
174 ng/mL, respectively), albeit less efficiently than ZIKV (EC50
of 9, 48, and 403 ng/mL, respectively, against ZIKV-Brazil;
Sapparapu et al., 2016). LALA variants of EDE1-B10 and ZIKV-
117, which inefficiently engage activating Fcg receptors (Hessell
et al., 2007; Figure 6B), had similar neutralization profiles as their
WT counterparts (Figure 6A).
We tested the cross-neutralizing anti-DENV and anti-ZIKV
mAbs for their ability to protect mice against SPOV infection.
In 8-week-old WT C57BL/6 mice, we passively transferred
1 mg of anti-Ifnar1-blocking mAb and a single 100 mg dose
(4 mg/kg) of EDE1-B10, ZIKV-117, ZIKV-A7, EDE1-A9, EDE1-
C4, ZIKV-C10, or an isotype control mAb (hu-CHK-152) 1 day
prior to SPOV-SA Ar94 inoculation. Mice treated with EDE1-
A9, EDE1-B10, EDE1-C4, and ZIKV-117 were completely pro-
tected against lethal infection and weight loss (Figures 6C and
6D). In comparison, mice treated with ZIKV-A7 or ZIKV-C10
were protected only partially with some weight loss and lethality
observed.
We evaluated two of the protective mAbs, EDE1-B10 and
ZIKV-117, for their efficacy as post-exposure therapy by as-
sessing impact on weight loss, mortality, and SPOV burden in
tissues. 8-week-old WT mice were given anti-Ifnar1 mAb
1 day prior to inoculation with SPOV-SA Ar94. Mice treated
with a single 100 mg (4 mg/kg) dose of EDE1-B10 or ZIKV-
117 mAbs 1 day after SPOV inoculation sustained no weight
loss and low (10%) rates of mortality compared to animals
treated with the isotype control hu-CHK-152 mAb (Figures 6E
and 6F). We also assessed therapeutic effects on viral burden
at 7 dpi using parental or LALA variants of EDE1-B10 or ZIKV-
117 mAbs or hu-CHK-152 control mAb (Figures 6G–6M).
EDE1-B10 parental and LALA mAbs both controlled infection
equivalently with markedly reduced or undetectable viral RNA
levels measured in the serum, brain, spleen, testis, kidney,
ileum, and eye. This finding suggests that the majority of the
protection afforded by EDE1-B10 mAbs is independent of Fc
effector functions and likely due to neutralizing activity. ZIKV-
117 mAb therapy also reduced SPOV infection in all tissues
compared to the control hu-CHK-152 mAb, but the viral RNA
levels were higher in the serum and spleen than in EDE1-B10
mAb-treated mice, indicating it was less potent. Unexpectedly,
less protection was seen with the ZIKV-117 LALA mAb than
parental mAb in the testis (30-fold) and ileum (5-fold), suggest-
ing that, for ZIKV-117, effector functions also contributed to
protection.
DISCUSSION
Because SPOV is the most closely related flavivirus to ZIKV, we
explored its tropism and pathogenesis in a murine model of
infection. Although few human SPOV cases are reported, its inci-
dence may be underestimated through misdiagnosis of infection
by more common arthropod-transmitted viruses (Haddow and
Woodall, 2016). The study of SPOV is timely, as there is now ev-
idence of introduction into the western hemisphere, with Culex
quinquefasciatus mosquitoes testing positive for virus in Haiti
in 2016 (White et al., 2018). Similar to ZIKV, peripheral infection
experiments with two African prototype strains of SPOV resulted
Figure 6. Neutralization and Protection against SPOV Infection by Cross-Reactive Anti-DENV or Anti-ZIKV mAbs
(A) Neutralization of SPOV-SA Ar94 by anti-DENV (EDE1-B10, EDE1-A9, and EDE1-C4) or anti-ZIKV (ZIKV-A7, ZIKV-C10, or ZIKV-117) mAbs as determined by
focus reduction neutralization test in Vero cells. LALA variants of EDE1-B10 and ZIKV-117 lacking the ability to bind FcgR also were tested. The data are
representative of three experiments, each performed in triplicate.
(B) Binding of parental and LALA variants of hu-CHK-152, ZIKV-117, and EDE1-B10 to human FcgRI (CD64) by ELISA.
(C–F) Prophylaxis and post-exposure treatment studies. 8-week-old C57BL/6 male mice were treated with anti-Ifnar1 mAb at day1 followed by subcutaneous
infection with 106 FFU of SPOV-SA Ar94.Mice alsowere treated at day1 (prophylaxis) or day +1 (post-exposure) with isotype-control mAb (hu-CHK-152) or with
a single 100-mg dose of EDE1-B10, EDE1-A9, EDE1-C4, ZIKV-A7, ZIKV-C10, or ZIKV-117. Survival (C and E) and weight (D and F) data were from two exper-
iments (n = 9 or 10 per group; survival: log rank test with Bonferroni post-test; weight: Kruskal-Wallis ANOVA with Dunnett’s post-test). The bracketed bar in-
dicates statistical significance (****p < 0.0001) for all mAb groups compared to hu-CHK-152 control mAb at the indicated time points. Colored stars were added
for particular mAbs with different statistical significance compared to hu-CHK-152 (*p < 0.05; **p < 0.01; ***p < 0.001).
(G–M) Post-exposure therapeutic studies. 8-week-old WT male mice were treated with anti-Ifnar1 mAb followed by subcutaneous inoculation with SPOV-SA
Ar94. At 1 dpi, mice were treated with a single 100-mg dose of isotype-control mAb (CHK-152), EDE1-B10 (parental or LALA), or ZIKV-117 (parental or LALA). At 7
dpi, SPOV RNA was measured in serum (G), brain (H), spleen (I), testis (J), kidney (K), ileum (L), and eye (M). Bars indicate median values collected from two
experiments (n = 10 per group). Statistical significance was determined (Kruskal-Wallis ANOVA with Dunn’s post-test: *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001).
Data points on the dotted lines were not measurable and given the arbitrary value of the LOD. For (D) and (F), error bars indicate SEM.
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in no disease in WT immunocompetent C57BL/6 mice. In
contrast, both SPOV strains disseminated widely when mice
were given a single dose of anti-Ifnar1-blockingmAb, suggesting
that, like ZIKV (Lazear et al., 2016; Rossi et al., 2016), SPOV fails
to antagonize the murine type I IFN response. Unlike ZIKV, this
cannot be overcome by replacement of mouse Stat2 with human
STAT2, as SPOV did not replicate efficiently in hSTAT2-KI mice,
whereas ZIKV does (Gorman et al., 2018). In the context of anti-
Ifnar1 mAb treatment, both strains of SPOV spread to visceral
and CNS tissues, persisted in tissues for weeks, and caused
morbidity and mortality in mice. SPOV, like ZIKV (Cugola et al.,
2016; Govero et al., 2016; Ma et al., 2016; Miner et al., 2016),
was able to infect the testis inmales and the placenta in pregnant
dams. Thus, at least in immunodeficient mice, SPOV shares
tropism features with ZIKV. Because of its genetic and family
relatedness, we tested anti-DENV- and anti-ZIKV-neutralizing
mAbs for their ability to cross-neutralize SPOV.We identified hu-
man mAbs recognizing the EDE epitope on DENV (EDE1-B10)
and domain II dimer epitope on ZIKV (ZIKV-117) that neutralized
SPOV infection and protected against infection and lethal chal-
lenge. Although these data suggest that vaccine or antibody
therapy strategies targeting other closely related flaviviruses
may inhibit SPOV, our studies are limited by the use of prototypic
African strains from the 1950s. As contemporary strains become
available, they will need to be evaluated for antibody reactivity
and neutralization patterns. The SPOV genome recently de-
tected in Haiti had 98.3% and 98.8% amino acid identity with
SPOV-Chuku and SPOV-SA Ar94 strains, respectively (White
et al., 2018).
The tissue tropism and pathogenesis of SPOV in mice has not
been extensively explored, although historical studies reported
virus-induced death in newborn and weanling mice after intra-
cranial inoculation (Kokernot et al., 1957). Our experiments in
anti-Ifnar1 mAb-treated adult mice are consistent with a recent
report evaluating SPOV-SA Ar94 infection in AG129 mice, which
lack the receptors required for both type I and type II IFN
signaling (McDonald et al., 2017). In AG129 mice inoculated
with SPOV-SA Ar94, nearly uniform mortality was observed after
subcutaneous or intraperitoneal inoculation, and this phenotype
correlated with high viral burden in the testis, epididymis, and
brain at the time of assessment. Our experiments extend these
findings in less immunocompromised mice and further define
the kinetics of infection and tissue tropism. At 7 days after sub-
cutaneous inoculation with SPOV-SA Ar94 or SPOV-Chuku, we
observed high levels of infection in many of the same tissues
that ZIKV infects (Lazear et al., 2016), including the spleen, kid-
ney, eye, testis, blood, gastrointestinal tract, and brain. More-
over, at 21 dpi, we detected viral persistence in the brain, spleen,
and kidney. In contrast to that seen with ZIKV in mice (Govero
et al., 2016; Ma et al., 2016) or in humans (Mansuy et al.,
2016a, 2016b), we did not observe persistence of SPOV RNA
in the testis. Although ejaculates from SPOV-inoculated AG129
males contained infectious virus, levels were substantially lower
than in ZIKV-infected males (McDonald et al., 2017), and thus,
the potential for sexual transmission of SPOV may be much
less than with ZIKV.
Viremia was prolonged in SPOV-infected mice treated with a
single dose of anti-Ifnar1 mAb. Although further studies defining
the source of this virus are warranted, persistence in lymphoid
tissues and kidneys was noted. Persistent viremia also was
observed after ZIKV infection of humans and non-human pri-
mates (Aliota et al., 2018; Mansuy et al., 2017; Nguyen et al.,
2017), including during pregnancy (Driggers et al., 2016; Gonce´
et al., 2018; Suy et al., 2016). As persistent ZIKV and SPOV
viremia occurs in the setting of induction of neutralizing anti-
bodies and specific CD8+ T cell responses, the immunological
basis for failure to control infection remains unexplained.
Analogous to studies with ZIKV (reviewed in Morrison and Dia-
mond, 2017) and more recent experiments with other neuro-
tropic flaviviruses (e.g., West Nile and Powassan viruses; Platt
et al., 2018), SPOV efficiently infected anti-Ifnar1 mAb-treated
pregnant dams and disseminated to the placenta and fetal
head. In contrast to ZIKV (Cugola et al., 2016; Miner et al.,
2016; Richner et al., 2017), infection of the placenta and fetus
inmice by SPOVwas not associated with placental insufficiency,
growth retardation, or microcephaly. Given the relatively low
levels of SPOV infection in the fetal heads at day 7 after maternal
infection, we were unable to define the cellular tropism in the
brain by RNA in situ hybridization techniques. Indeed, we could
not recover infectious SPOV from fetal heads despite detecting
viral RNA. Our inability to detect infectious SPOV in the fetal
heads may be because (1) virus in the fetus head is neutralized
by maternal antibodies that cross the placental barrier and/or
(2) the level of infectious virus is below our limit of detection;
qRT-PCR of viral RNA is 100-fold more sensitive. The differen-
tial outcomes in fetuses also may be due to differences in
tropism of SPOV for certain neuroprogenitor cells or disparity
in capacity of SPOV to cause cell injury and death. Notwith-
standing the absence of effect on fetal resorption and growth,
the long-term neurodevelopmental and behavioral conse-
quences of congenital SPOV infection in the fetal head remain
to be assessed.
An unexpected observation was that both SPOV strains
caused infection and swelling in the feet of mice, reminiscent
of the disease observed following arthritogenic alphavirus infec-
tions (Morrison et al., 2011). At 5 dpi, high numbers of leukocytes
from multiple immune cell lineages accumulated in joint-associ-
ated tissues of SPOV-Chuku-infected mice. Although arthralgia
is a commonly described symptom after flavivirus infection in
humans (Pierson and Diamond, 2013), frank joint swelling is
not typical. Nonetheless, in one study characterizing the ZIKV
epidemic in Brazil in 2015, 23% of documented cases had joint
swelling (Cerbino-Neto et al., 2016). In a study in India, 4% of
DENV-infected individuals experienced acute joint swelling (Tar-
aphdar et al., 2012). Thus, joint swelling appears to occur, albeit
with low frequency, with some flavivirus infections. We observed
high levels of SPOV-SA Ar94 or SPOV-Chuku infection at 7 dpi
in the musculoskeletal tissues of the ipsilateral and contralateral
feet. Remarkably, SPOV-Chuku was measurable at 21 dpi, even
in mice that had received no blockade of type I IFN signaling.
Although further studies are required, we speculate that the early
replication in this tissue (immediately after inoculation) could
result in local immune evasion that might not occur in other distal
tissues where paracrine spread of type I IFN creates an antiviral
state. The degree of foot swelling did not correlate directly
with viral burden, as greater swelling was observed after
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SPOV-Chuku infection, which accumulated to lower levels.
As joint swelling after chikungunya virus infection in mice is
attributed to the production of pro-inflammatory cytokines and
chemokines and infiltration and activation of immune cell sub-
sets (Fox and Diamond, 2016), the differences in phenotype be-
tween the two SPOV strains might be explained by distinct
inflammatory responses.
Usingmouse and human convalescent sera, we confirmed the
serological relatedness of SPOV to ZIKV and distance of SPOV
to DENV2, as judged by differences in neutralization titers. These
results suggest that, in ZIKV-endemic regions (or future ZIKV-
vaccinated regions), it may be difficult for SPOV to emerge due
to cross-immunity. In contrast, because SPOV and ZIKV immune
sera had limited neutralizing activity against DENV, and corre-
spondingly, DENV immune sera had limited inhibitory activity
against SPOV infection, SPOV could emerge in DENV-immune
or vaccinated regions, contingent on its ability to propagate in
mosquito species capable of epidemic transmission.
We also observed reciprocal enhancement of SPOV, ZIKV,
and DENV2 infection by the different murine and human sera.
Enhanced infection occurs when cross-reactive, non-neutral-
izing quantities of antibodies bind virus and facilitate infection
of cells expressing Fc-g receptors. A feature of DENV pathogen-
esis is that antibodies to one serotype can exacerbate infection
with a second serotype via antibody-dependent enhancement
(Culshaw et al., 2017; Halstead, 1979). Nonetheless, antibody-
enhanced infection in cell culture has been demonstrated for
many viruses without evidence of worsened disease in humans.
Thus, epidemiological evidence from humans will be needed to
establish whether clinically relevant enhancement of DENV,
ZIKV, or SPOV pathogenesis occurs in the setting of pre-existing
heterologous flavivirus immunity.
We evaluated whether particular anti-ZIKV or anti-DENV hu-
man neutralizing mAbs could protect against SPOV infection
as a prelude for possible future use in humans. Two classes of
cross-reactive human Abs (which may not be generated during
natural infection by all individuals) showed substantial inhibitory
activity against SPOV infection in mice: EDE1 anti-DENV mAbs
and ZIKV-117 mAbs. (1) EDE1 mAbs were isolated from DENV-
infected patients, are highly neutralizing for multiple DENV sero-
types (Dejnirattisai et al., 2015), cross-neutralize ZIKV infection
(Barba-Spaeth et al., 2016), and protect against vertical trans-
mission of ZIKV in animal models (Fernandez et al., 2017).
EDE1 mAbs engage contact residues in DI, DII, and DIII in the
context of a quaternary E protein dimer epitope (Barba-Spaeth
et al., 2016; Rouvinski et al., 2015). Our experiments showed
potent cross-neutralization of SPOV by the EDE1-B10 mAb
and an ability to protect against lethal challenge and control
dissemination to distant organs. Moreover, abrogation of inter-
actions with FcgRs and complement components by introduc-
tion of a LALA mutation in the Fc domain (Hessell et al., 2007)
did not impact therapeutic activity of EDE1-B10, suggesting
that the majority of its activity in vivo is due to direct neutraliza-
tion. (2) ZIKV-117 mAb neutralizes ZIKV strains of the African
and Asian lineages and can reduce fetal infection and death in
mice (Sapparapu et al., 2016). ZIKV-117 binds at the E protein
dimer interface, which likely prevents the requisite reorganiza-
tion of E protein monomers into fusogenic trimers to escape
the endosome (Hasan et al., 2017). Initial studies suggested
that ZIKV-117 might be virus type specific because it failed to
bind to DENV-infected cells or purified WNV E protein (Sappar-
apu et al., 2016); our study reveals that ZIKV-117 can recognize
the more closely related SPOV and inhibit its infection in cell cul-
ture. Although ZIKV-117 could protect against SPOV-induced
clinical disease, it showed less antiviral activity than EDE1-
B10. Moreover, some of the therapeutic activity of ZIKV-117
was lost in the LALA variant, even though in vitro neutralization
of the parental and LALA versions was virtually identical. Collec-
tively, these results suggest that less potently neutralizing mAbs
likely require adjunctive Fc-effector functions to mediate optimal
protection in vivo.
In summary, we developed a murine model of infection and
pathogenesis of SPOV that has similarities and differences
with the closely related ZIKV. SPOV does not replicate efficiently
in immunocompetent mice after peripheral inoculation, likely due
to a failure to antagonize the IFN responses of its non-natural
host, the mouse. However, if type I IFN signaling is blocked,
SPOV can disseminate to many of the same organs as ZIKV
and result in lethal or persistent infection. Uniquely, SPOV infec-
tion in the foot resulted in clinically observable swelling and im-
mune cell infiltrates, which are not observed after ZIKV infection
in mice. Although SPOV also disseminated to the maternal-fetal
interface in pregnant dams, in contrast to ZIKV, it failed to cause
extensive placental or fetal injury. Finally, we identified several
human cross-reactive mAbs derived from ZIKV- or DENV-in-
fected patients that potently neutralized SPOV infection in cell
culture. Our passive transfer studies in mice suggest that some
classes of cross-reactive mAbs (e.g., EDE1 mAbs) may have
substantial therapeutic activity against SPOV in vivo, which
may be relevant to vaccine or treatment strategies, should
SPOV spread further in the Americas or other continents.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses
ZIKV strain Dakar 41525 (Senegal, 1984) and SPOV strains SA Ar94 (South Africa, 1955) and Chuku (Nigeria, 1952) were provided by
theWorld Reference Center for Emerging Viruses and Arboviruses (R. Tesh and S. Weaver, University of Texas Medical Branch). The
mouse-adapted ZIKV strain Dakar 41525 has been published (Gorman et al., 2018). Studies with SPOV and ZIKV were conducted
under biosafety level 2 (BSL2) and animal (A-BSL3) containment at Washington University School of Medicine with Institutional
Biosafety Committee approval.
SPOV and ZIKV stocks were propagated in Vero cells after inoculating at a multiplicity of infection (MOI) of 0.01 and incubating at
37C for 40 h. Virus stocks were propagated in mycoplasma-free Vero cells and titrated by focus-forming assay. Infected cell foci
were detected at 48 h after infection, following fixation with 1% paraformaldehyde and incubation with 500 ng/ml of flavivirus
cross-reactive mouse monoclonal antibody E60 (Oliphant et al., 2006) for 2 h at room temperature. After incubation for 1 h with a
1:5,000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma), foci were detected by addition of True
Blue substrate (KPL). Foci were analyzed with a CTL ImmunoSpot instrument.
Recombinant viral proteins
ZIKV envelope (E) ectodomain (strain French Polynesia, 2013) was purchased commercially (Native Antigen). A fragment of the open
reading frame from Spondweni virus strain SM-6 V-1 (NCBI Reference Sequence YP_009222008.1) encoding E protein residues
2-412 was inserted into pET21(a) between the NdeI and XhoI sites. The clone contains a methionine codon for initiation contributed
by the NdeI site and a stop codon before the XhoI site. The protein was produced in BL21(DE3) cells after a 4 h induction with 1 mM
IPTG at 37C and refolded in arginine buffer following a published protocol (Zhao et al., 2016).
Serum from ZIKV- and DENV-immune subjects
We studied nine subjects in the United States with previous ZIKV (n = 5) or DENV (n = 4) infection. No sample size estimation was
performed for these studies. Subjects were allocated to experimental groups based on their known infection status. The studies
were approved by the Institutional Review Board of Vanderbilt University Medical Center; samples were obtained after informed con-
sent was obtained by the Vanderbilt Clinical Trials Center.
Ethics statement for mouse studies
This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington
University School of Medicine (Assurance number A3381-01). Inoculations were performed under anesthesia induced and main-
tained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
Mouse infection experiments
WTC57BL/6mice were purchased commercially (Jackson Laboratory, 000664). Eight week-oldmice were inoculated by subcutane-
ous route in the footpad with 106 (SPOV-SA Ar94) or 105 (SPOV-Chuku) focus-forming units (FFU) in a volume of 50 ml. One-day prior
to virus inoculation, mice were treated with 0.5, 1, 1.5, or 2 mg of an Ifnar1-blocking mAb (MAR1-5A3 (Sheehan et al., 2006)) by intra-
peritoneal injection. Survival and weight loss were monitored for 21 days, and some animals were harvested at 7 dpi for viral burden
analysis. In some experiments, mice were administered before (day 1) or after (day +1) virus inoculation a single 100 mg (4 mg/kg)
Continued
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Oligonucleotides
ZIKV-Dakar titering primers Gorman et al., 2018 See Table S2
SPOV-SA Ar94 titering primers This paper See Table S2
SPOV-Chuku titering primers This paper See Table S2
Software and Algorithms
Prism GraphPad Version 7.0h
FlowJo FlowJo Version 10.0.7
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dose of cross-reactive human IgG1 mAbs (ZIKV-117 (Sapparapu et al., 2016), EDE1-A9 (Barba-Spaeth et al., 2016), EDE1-B10 (Fer-
nandez et al., 2017), EDE1-C4 (Barba-Spaeth et al., 2016), ZIKV-A7 or ZIKV-C10 (W.D. and G.R.S., unpublished data), or an isotype
control humanized mAb (hu-CHK-152 (Pal et al., 2013)) or LALA (leucine to alanine substitutions) variants (Fernandez et al., 2017;
Sapparapu et al., 2016).
For pregnancy studies, WT C57BL/6 male and female mice were mated. At embryonic day E5.5, dams were treated with 0.5 or
1 mg anti-Ifnar1 mAb by intraperitoneal injection. At E6.5, dams were inoculated with 106 FFU of SPOV-SA Ar94 by a subcutaneous
route in the footpad. Animals were euthanized at E13.5 or E18, and placentas, fetuses, andmaternal tissues were harvested depend-
ing on the experiment.
METHOD DETAILS
Measurement of viral burden
SPOV-infected mice were euthanized at 7, 14, or 21 dpi and perfused extensively with 20 mL of PBS. Brain, spleen, testis, kidney,
ileum, and eye tissues were harvested, weighed, and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life
Science) in 300 mL of DMEM media supplemented with 2% heat-inactivated FBS. Blood was collected and allowed to clot at
room temperature; serum was separated, and all tissue homogenates were clarified by centrifugation at 6,000 x g for 5 min and
stored at 80C. RNA was extracted using an Applied Biosystems 5x MagMax RNA 96 viral isolation kit (Thermo Scientific) and a
Kingfisher duo prime extraction machine (Thermo Scientific). With some samples, viral burden was determined by plaque assay
on Vero cells as described (Miner et al., 2016) except 2% methylcellulose instead of agarose was used for the overlay. ZIKV RNA
levels were determined by one-step quantitative reverse transcriptase PCR (qRT–PCR) using an Applied Biosystems Taqman
RNA-to-Ct 1-step kit (Thermo Scientific) on an ABI 7500 Fast Instrument using standard cycling conditions. Previously designed
primer/probe sets were used for the SPOV (Haddow et al., 2016) and ZIKV Dakar 41525 (Lanciotti et al., 2008) strains, and
primer/probe sets were designed for the SPOV strains (Table S1). Viral burden was expressed on a log10 scale as ZIKV RNA equiv-
alents per gram or ml after comparison with a standard curve produced using serial tenfold dilutions of ZIKV RNA (Govero et al.,
2016). Separate standard curves were made for each SPOV strain.
Histology and RNA in situ hybridization
Placentas and fetuses from uninfected or SPOV-infected pregnant mice (E13.5) were collected, fixed overnight in 4% paraformalde-
hyde (PFA) in PBS, and cut into 3-mm-thick sections followed by hematoxylin and eosin (H&E) staining. RNA ISHwas performed using
RNAscope 2.5 (Advanced Cell Diagnostics) according to the manufacturer’s instructions. PFA-fixed paraffin-embedded tissue sec-
tions were deparaffinized by incubating for 60 min at 60 C. Endogenous peroxidases were quenched with H2O2 for 10 min at room
temperature. Slides were boiled for 15 min in RNAscope Target Retrieval Reagents and incubated for 30 min in RNAscope Protease
Plus before probe hybridization. The probe targeting SPOV RNA was designed and synthesized by Advanced Cell Diagnostics
(Catalog #512151). Tissues were counterstained with Gill’s hematoxylin and visualized using bright-field microscopy.
RVP neutralization and enhancement assays
Pseudo-infectious RVP production has been described previously (Mukherjee et al., 2014). Briefly, RVPs were produced by the co-
tranfection of a GFP-expressing WNV sub-genomic replicon with an expression vector encoding viral structural proteins (C-prM-E)
in trans using HEK293T cells. Virus-containing supernantants were harvested and filtered 3 to 7 days post-transfection. Plasmids
encoding the structural genes (ZIKV, H/PF/2013; SPOV, SM-6 V-1; DENV2, 16681) were generated using previously described
methods (Ansarah-Sobrinho et al., 2008; Dowd et al., 2016). RVPs were diluted sufficiently to ensure antibody excess and incubated
with an equivalent volume of serially diluted mouse or human serum or mAbs for 1 h at 37C. The resulting immune complexed were
used to infect Raji-DCSIGNR cells and incubated at 37C for 36 to 48 h. Cells were fixed with 3% paraformaldehyde, and GFP
expression was detected by flow cytometry. The resulting data was analyzed and dose-response curves were fit using nonlinear
regression to calculate the sera dilution required to inhibit infection by 50% (EC50) (Prism 7 Software; GraphPad). To measure anti-
body-dependent enhancement antibody-RVP immune complexes were generated as described above and used to infect Fc-g re-
ceptor-expressing K562 cells for 36 to 48 h at 37C. RVPs were fixed, infection was detected by flow cytometry and scored as a
function of GFP expression.
Antibody-virus neutralization assays
Serial dilutions ofmAbswere incubated with 102 FFU of different SPOV strains for 1 h at 37C. ThemAb–virus complexes were added
to Vero cell monolayers in 96-well plates for 1 h at 37C. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM.
Plates were fixed 40 h later with 1% PFA in PBS for 1 h at room temperature. The plates were incubated with 500 ng/ml of E60
and developed in a focus-forming assay as described above. For serum antibody neutralization assays, both SPOV and ZIKV-
immune mouse sera were heat-inactivated for 30 min at 60C. Sera then was diluted in 96-well round bottom (1:20, 1:60, 1:180,
1:540, 1:620, 1:4860, 1:14580) and mixed with SPOV SA Ar94 or ZIKV Dakar 41525 (102 FFU of SPOV or ZIKV per well). Samples
were added to Vero cell monolayers in 96-well plates and processed by focus-forming assay as described above.
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Antibody responses
The levels of SPOV and ZIKV-specific IgM and IgG were determined using an ELISA against purified SPOV and ZIKV E protein,
respectively. Polystyrene ELISA plates were coated with 4 mg/ml of recombinant SPOV or ZIKV E protein. Plates were blocked
with 2% BSA in PBS containing 0.05% Tween-20 (blocking buffer), and then incubated for at least 1 h. Heat-inactivated serum sam-
ples from SPOV or ZIKV-infected mice were diluted in blocking buffer and then incubated for at least 2 h. Bound antibodies were
detected using biotin-labeled goat anti-mouse IgM and IgG antibodies and streptavidin-HRP. End-point titers for SPOV and ZIKV
E-specific IgM and IgG concentration were defined as reciprocal serum dilutions that corresponded to two times the average OD
values obtained with BSA.
T cell assays
Splenocytes from naive, SPOV, and ZIKV-infected mice at 8 days after infection were plated (1 3 106 per well, in 200 ml) in 96-well
round-bottom plates and stimulated with 1 mg of an immunodominant ZIKV-derived, Db-restricted peptide E294-302 for 6 h at 37
C in
the presence of brefeldin A, as previously detailed (Elong Ngono et al., 2017). Cells without stimulation and splenocytes from naive
animals were used as negative controls. After incubation, cells were stained with antibodies against CD3ε (Alexa Fluor 488, 145-
2C11, BioLegend, 1:100), CD4 (eFluor 450, GK1.5, Invitrogen, 1:100), CD8b (PerCP/Cy5.5, YTS156.7.7, BioLegend, 1:200), CD19
(APC/Cy7, 6D5, BioLegend, 1:200), and CD44 antigens (PE/Cy7, IM7, BioLegend, 1:100). After fixation and permeabilization using
Cytofix/Cytoperm buffer (BD Biosciences), cells were incubated with anti-IFNg (Alexa Fluor 647, XMG1.2, BioLegend, 1:100), and
anti-granzymeB (PE, GB11, Invitrogen, 1:100) mAbs. Samples were processed on a LSRII flow cytometer and analyzed using FlowJo
software X 10.0.7.
Flow cytometric analysis
Uninfected and SPOV-Chuku infected mice (both treated with 1 mg anti-Ifnar1 at day 1) were euthanized at 5 dpi and perfused
extensively with 20 mL of PBS. The inoculated foot was skinned and disarticulated from the tibia. Tissues were incubated for 2 h
at 37C in RPMI with collagenase (2.5 mg/mL, Sigma, C-0130), DNase I (Sigma, D5025), and 10% FBS. Digested tissue was passed
through a 100-mmstrainer, and cells were separated by centrifugation (200 x g, 5min). Cells were incubated with antibodies to CD16/
32 (93, Biolegend, 1:100) for 10 min at 4C and then stained with a fixable viability dye (eFluor 506, eBioscience) and antibodies to
CD45 (BUV395, 30-F11, BD Biosciences, 1:200), CD3ε (Alexa Fluor 488, 145-2C11, BioLegend, 1:200), CD4 (Brilliant Violet 785,
RM4-5, Biolegend, 1:200), CD8b (PerCP/Cy5.5, YTS156.7.7, BioLegend, 1:200), B220 (Brilliant Violet 711, RA3-6B2, Biolegend,
1:200), CD11b (PE/Dazzle, M1/70, Biolegend, 1:200), CD11c (PE-Cy7, HL3, BD Biosciences, 1:200), Ly6G (PerCP/Cy5.5, 1A8,
Biolegend, 1:400), Ly6C (Pacific Blue, HK1.4, 1:200, Biolegend), NK1.1 (PE, PK136, Biolegend, 1:200), and MHCII (Alexa Fluor
700, M5/114.15.2, Biolegend, 1:200). Datasets were acquired on a LSRII flow cytometer and analyzed using FlowJo software X
10.0.7.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data analysis
All statistical analysis was performed with GraphPad Prism software. Details of statistical tests used to analyze experiments are
described in the Figure Legends. Kaplan-Meier survival curves were analyzed by the log rank test with a Bonferroni post-test,
andweight change or foot swellingwas evaluatedwith a Kruskal-Wallis ANOVAwith a Dunnett’s post-test correction. For viral burden
analysis, the log10 transformed titers were analyzed by Mann–Whitney test or a Kruskal–Wallis ANOVA with Dunn’s post-test correc-
tion. A P value of < 0.05 established statistically significant differences.
DATA AND SOFTWARE AVAILABILITY
All data is available upon request to the lead contact author. No proprietary software was used in the data analysis.
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Figure S1. Lack of viral infection in SPOV-infected hSTAT2-KI mice. Related to Figure 1. 
Five week-old hSTAT2 male mice were inoculated with 106 FFU of SPOV-SA Ar94. Serum (3 or 
7 dpi) and tissues (spleen, kidney, testis, and brain; 7 dpi) were harvested, and SPOV RNA levels 
were measured by RT-qPCR and normalized to a standard curve. Data are from two experiments 
with n = 10 mice per time group. The limit of detection is shown. In all experimental RT-PCR 
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Figure S1
 Figure S2. Neutralization and enhancing activity of serum-derived antibodies generated in mice. 
Related to Figure 5. Neutralization and antibody-dependent enhancement (ADE) assays were 
performed using RVPs representing three flavivirus strains (ZIKV, SPOV, and DENV2). Naive and 
convalescent mouse serum was diluted serially and incubated with indicated RVP strains. Immune 
complexes were used to infect Raji-DCSIGNR cells to measure neutralization or Fcg-expressing 
K562s cells to measure ADE. Infection was scored by GFP expression after 24 to 48 h using flow 
cytometry. For neutralization assays, data was normalized (left y-axis), and antibody-dose response 
curves were fit using nonlinear regression analysis to determine the dilution of sera at half-maximal 
neutralization of infection (EC50). For ADE assays, antibody binding was measured as the percentage 
of GFP expression (right y-axis). Representative neutralization curves and ADE line graphs of naive 
(A-D), ZIKV-immune (E-I), and SPOV-immune (J-N) mice against indicated RVPs are shown. Error 
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Figure S3. Antibody neutralizing and enhancing activity with convalescent serum from ZIKV-
infected humans.  Related to Figure 5. Neutralization and antibody-dependent enhancement (ADE) 
assays were performed using RVPs representing three flavivirus strains (ZIKV, SPOV, and DENV2). 
Convalescent human serum from ZIKV infected individuals was serially diluted and incubated with 
indicated RVP strains. Immune complexes were used to infect Raji-DCSIGNR cells to measure 
neutralization or Fcg-expressing K562s cells to measure ADE. Infection was scored through GFP 
expression after 24 to 48 h using flow cytometry. For neutralization assays, data was normalized (left 
y-axis) and antibody-dose response curves were fit using nonlinear regression analysis. For ADE 
assays, antibody binding was measured as the percentage of GFP expression (right y-axis). 
Representative neutralization curves and ADE line graphs of convalescent sera from ZIKV-infected 
subjects (A-E) against indicated RVPs are shown. Error bars indicate the range in infectivity of 



























































































Figure S4. Antibody neutralizing and enhancing activity with convalescent serum from DENV-
infected humans.  Related to Figure 5.  Neutralization and antibody-dependent enhancement (ADE) 
assays were performed using RVPs representing three flavivirus strains (ZIKV, red; SPOV, blue; 
DENV2, green). Convalescent human serum from DENV-infected individuals was serially diluted, 
incubated with indicated RVP strains to ensure steady-state binding. Antibody-antigen immune 
complexes were used to infect Raji-DCSIGNR cells to measure neutralization or Fcg-expressing 
K562s cells to measure ADE. Infection was scored by GFP expression after 36-48 h using flow 
cytometry. For neutralization assays, data was normalized (left y-axis) and dose response curves were 
generated using nonlinear regression analysis. For ADE assays, antibody binding was measured as the 
percentage of GFP expression (right y-axis). Representative neutralization curves and ADE line graphs 
of DENV convalescent sera (humans A-D) against indicated RVPs are shown from two independent 














































































Table S1. List of Primers. Related to Figure 2.  
 
Primer Name Primer Sequence (5’-3’) 











SPOV primers  
SPOV RNA: 
Forward 
5’-ACCAGTGACACCAATAGCATG-3’ 
 
SPOV RNA: 
Reverse 
5’-CAAACGGAGGGTCAATCTCG-3’ 
 
SPOV RNA: 
Probe 
5’-/56-
FAM/CACGGAAAG/ZEN/TGGAGCAAACTCAAAGATG/3IABkFQ/-3’ 
 
	
 
 
	
